Morningstar's bullish on biotech; Pfizer's among the picks
Biotech stocks have had a rough go so far this year, falling 12% compared with a 13% gain for the S&P 500. Morningstar sees opportunities. |!| Cottonwood
Biotech stocks have had a rough go so far this year, falling 12% compared with a 13% gain for the S&P 500. Morningstar sees opportunities. |!| Cottonwood